Press Room
Panaxia Logo:
- 2 January 2022
Panaxia and Neuraxpharm will be the first companies to exclusively launch Medical Cannabis Extracts for Inhalation in Europe
- 21 June 2021
Panaxia Israel continues growth trend in the first quarter of 2021: reports record revenues of 19.7 million
- 31 May 2021
Panaxia and Leriva announced: Exclusive collaborations in Greece
- 19 May 2021
Panaxia ramping up expansion into Europe and stepping away from distribution and logistics operations in Israel
- 30 April 2021
Panaxia Israel announces estimated record revenues of at least 19 million in Q1 2021
- 12 April 2021
Panaxia closes out 2020 tripling revenues to a record-breaking 60.7 million
- 31 March 2021
Panaxia announces first retail sales of its products for patients in Germany
- 3 February 2021
Government of Cyprus selects Israeli company Panaxia: Will purchase its premium oils for the country's medical cannabis patients
- 3 February 2021
Unprecedented international achievement for Panaxia: selected as one of the four main winners in the French government tender for regulation of the medical cannabis industry
- 26 January 2021
Panaxia continues its upward trend: Ends Q3 with record revenues of 16.8 million
- 29 November 2020
Panaxia and Neuraxpharm expand strategic collaboration to France with medical cannabis
- 22 November 2020
Panaxia is the first Israeli company to receive a marketing permit for medical cannabis products in Germany
- 9 November 2020
Panaxia Global Reports that Panaxia Israel ended the 3rd quarter of 2020 with record revenues
- 12 October 2020
Panaxia Global Reports: Panaxia Israel Continues to Grow
- 30 August 2020
Panaxia’s agreement with international pharma Neuraxpharm is finalized
- 17 July 2020
Panaxia Global Reports Record Revenues of its Israeli operations: The preliminary outlook projects at least 14 million in Q2 2020. Completes 11 consecutive quarters of growing revenues
- 8 July 2020
Blazing The Trail To European Exports: Panaxia Israel Announces receipt of EU-GMP Certification, Required For The Manufacture And European Export Of Medical Cannabis And Advanced Products
- 10 June 2020
Panaxia Global Reports Record Revenues for its Israeli activity In the First Quarter Of 2020
- 8 June 2020
A breakthrough in the global medical cannabis market: Neuraxpharm enters the medical cannabis market as the first-ever European pharmaceutical company to market medical cannabis products
- 1 April 2020
Panaxia is preparing for European sales: Announces an agreement for temporary use rights in an R&D facility in Malta for the commercial production and marketing of its European cannabis products in Europe
- 30 March 2020
Panaxia Israel Announces successful completion of the capital raising of 23 million ILS in privately allocated by Israeli institution investors and the company’s controlling shareholders.
- 26 March 2020
Hemp-based products of Panaxia US and partner Ultra Health receive distribution and manufacturing license: Having passed the New Mexico NMED audit, Panaxia US received a first-of-its-kind license to manufacture and distribute products throughout the US
- 26 March 2020
A first-of-its-kind permit to export cannabis oil from the US to Israel was granted to Panaxia (TASE:PNAX) and its partner Ultra Health
- 20 March 2020
First distribution agreement for Israeli medical cannabis products in Danish market: Panaxia Israel will distribute and sell medical cannabis oil through STENOCARE, the largest distributor of medical cannabis stock in Denmark
- 12 March 2020
Excellent clinical trial results for leading Panaxia products: Results prove efficacy of absorption in the blood and safety of tablets, suppositories and inhaled cannabis extract
- 10 December 2019
Joining forces with Prof. Aaron Ciechanover: Prof. Markus Veit, member of the German Pharmacopoeia and a world-renowned expert in the registration of herbal medicinal drugs, has joined the advisory committee to Panaxia’s board
- 19 November 2019
Panaxia joins the front line of the largest companies in the world: The first and only company in Israel to successfully complete a European regulation audit towards receiving a European EU-GMP manufacturing standard which enables export of pharmaceutical cannabis products to Europe
- 30 October 2019
Professor Aaron Ciechanover, Nobel Laureate in Chemistry, was appointed senior member in the advisory committee of Panaxia directorate
- 20 September 2019
The merger deal of Panaxia Israel and Public company Herodium reaches the finish line
- 18 September 2019
Panaxia Israel publishes its financial results for the first-half of 2019
- 8 September 2019
A senior investment banker at Wall Street joins Panaxia: Orit Freedman Weissman, former partner at Goldman Sachs New-York, has been appointed Director in Panaxia
- 28 May 2019
Panaxia Israel signed a Letter of Intent with Cannbit for the development of cannabis-based prescription drugs to relieve symptoms of ADHD and Fibromyalgia
- 14 May 2019
Panaxia and Rafa sign a collaboration agreement with PlantEXT to research and manufacture the first medical cannabis suppositories intended for patients suffering from inflammatory bowel disease (IBD, Crohn's and colitis)
- 1 May 2019
Revolutionizing Breakthrough for those suffering from chronic pain: a clinical research with medical cannabis sublingual tablets is currently on its way
- 23 April 2019
Jonathan Kolber appointed Chairman of Panaxia Israel; Will also join as a shareholder in Panaxia Global with a 4-million-dollar investment
- 24 March 2019
Good news for cancer patients treated with medical cannabis and suffering from breakthrough cancer pain: Panaxia has ended "In Human" phase in its clinical trial for one-of-a-kind metered-dose cannabis inhaler
- 26 February 2019
Professor Aaron Ciechanover, Nobel Laureate in Chemistry, was appointed senior member in the advisory committee of Panaxia directorate
- 14 February 2019
- 19 May 2022
